Our laboratory is engaged in the discovery and development of new molecule designs for the use in therapy. A major focus is the development of bicyclic peptide ligands of disease targets using a combinatorial approach based on phage display.
- Post-doc position: Synthesis and high-throughput screening of (peptide) macrocycle libraries for the development of inhibitors of protein-protein interactions
- PhD position: Phage display selection of proteolytically stable cyclic peptides for the development of oral peptide therapeutics
Selected Recent Publications
Cyclization of peptides with two chemical bridges affords large scaffold diversities
Kale, S.S., Villequey, C., Kong, X.D., Zorzi, A., Deyle, K. and Heinis, C.
Nature Chemistry, 2018
Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
Zorzi, A., Middendorp, S.J., Wilbs, J., Deyle, K. and Heinis, C.
Nature Communications, 2017
Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity
Middendorp, S.J., Wilbs, J., Quarroz, C., Calzavarini, S., Angelillo-Scherrer, A. and Heinis, C.
Journal of Medicinal Chemistry, 2017
A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation
Baeriswyl, V., Calzavarini, S., Chen, S., Zorzi, A., Bologna, L., Angelillo-Scherrer, A., and Heinis, C.
ACS Chemical Biology, 2015
Dithiol amino acids can structurally shape and enhance the ligand-binding properties of polypeptides
Chen, S., Gopalakrishnan, R., Schaer, T., Heinis, C., Marger, F., Hovius, R., Bertrand, D., Pojer, F. and Heinis, C.
Nature Chemistry, 2014